Next, we assessed the effect of three months of SUL-138 treatment on a key pathological hallmark of AD, the formation of amyloid plaques, in the hippocampus of APP/PS1 mice (Fig. 1G/H, S3). The gene discussed is APP; the disease is Alzheimer disease.